AADI BIOSCIENCE INC AADI 深 滬
已收盤 03-18 16:00:00 美东时间
2.05
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 2.05
- 總市值 9489.16万
- 52周最高 3.812
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.21
- 委 比 0.00%
- 總股本 4628.86万
- 歷史最高 65.25
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.21
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Whitehawk Therapeutics: Strategic Shift and Financial Outlook
Aadi Bioscience, Inc. ( ($AADI) ) has released its Q4 earnings. Here is a break...
2025-03-20 11:53
Aadi Bioscience, Now Whitehawk Therapeutics Reports Q4 2024 GAAP EPS $(0.67) Misses $(0.35) Estimate, Sales $7.239M Up From $6.326M YoY
Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.35) by 91.43 percent. This is a 11.67 percent decrease over losses of $(0.60) per share from
2025-03-19 20:55
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company
New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 20...
2025-03-19 04:00
Aadi Bioscience Announces Closing of $100 Million PIPE Financing
MORRISTOWN, N.J., March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to...
2025-03-05 05:05
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer
Seasoned Oncology Leader Brings Extensive ADC Expertise to Support Company's New Pipeline MORRISTOWN, N.J., Feb. 18, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced...
2025-02-18 21:00
中国创新药资产再受追捧：济煜医药海外授权推动交易对手股价翻倍
RAPT Therapeutics与济煜医药达成独家许可协议，获得新型长效IgE抗体JYB1904在全球（除大中华区外）的开发及商业化权利。 当地时间202...
2024-12-24 22:22
Aadi Bioscience’s Strategic Agreements and Funding Moves
An announcement from Aadi Bioscience ( ($AADI) ) is now available. Aadi Bioscie...
2024-12-20 19:31
Aadi Bioscience rockets 72% on key updates
Aadi Bioscience (NASDAQ:AADI) stock price soared 72% on Thursday during after market hours of trading as it signed an exclusive license agreement for Three-Asset ADC portfolio developed through a coll...
2024-12-20 15:37
眼科生物科技公司「拨康视云-B」第三次递表，处于临床三期烧钱阶段
来源：活报告 摘要：拨康视云于2024年12月2日向港交所第三次递交招股书，拟在香港主板上市，联席保荐人为瑞银集团、建银国际和华泰国际。 公司是临床阶段...
2024-12-03 17:46
